Prediction of the risk and progression of cervical intraepithelial neoplasias associated with papillomavirus infection


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Objective. To reveal the specific features of a change in human mRNA gene expression in patients with human papillomavirus (HPV)-associated diseases of the cervix uteri for the prediction of the risk and progression of cervical intraepithelial neoplasias. Subjects and methods. The prospective investigation enrolled 225 women aged 18 to 60 years. The examination included collection of complaints, history data, gynecological status determination, expanded colposcopy, and molecular biological and morphological studies. The molecular biological studies involved real-time multiplex PCR assay with the detection of results for the quantification and typing of HPV 21 and the determination of the mRNA expression of the genes MKI 67 (KI67), CTSL2, CDKN2A (P16), ESR1, PGR, BCL2, BAX, BAG1, CD68, SCUBE2, and PTEN. Results. There were 5 groups: 1) 45 (20%) HPV-negative patients (a control group); 180 (80%) HPV-positive patients divided into 4 groups: 2) 56 (24.9%) with latent and subclinical papillomavirus infection (PVI); 3) 50 (22.2%) with low-grade squamous intraepithelial lesion (LSIL); 4) 55 (24.4%) with high-grade squamous intraepithelial lesion; 5) 19 (8.5%) with cancer of the cervix uteri (CCU). Conclusion. The investigation showed differences in the mRNA expression level of potential cervical epithelial tumor markers in patients with cervical neoplasias of varying degrees or CCU and in healthy women. The increased mRNA expression of the genes MKI67 (KI67) and CDKN2A (P16), the decreased expression of PGR, BCL2 in combination with high-risk HPV types, and an abnormal colposcopic pattern correlate with the outcomes of LSIL and may be regarded as possible biomarkers for the prediction of the course of already developed neoplasia; in HPV carriage as possible biomarkers for the prediction of evolving neoplastic transformation of the cervical epithelium. The comprehensive analysis of clinical and anamnestic parameters and the identification of molecular genetic markers increase the risk of disease progression.

Full Text

Restricted Access

About the authors

Olga Vladimirovna Burmenskaya

Research Center of Obstetrics, Gynecology, and Perinatology, Ministry of Health of Russia

Email: o_bourmenskaya@oparina4.ru
Molecular-genetic Laboratory Researcher

Niso Mirzoevna Nazarova

Research Center of Obstetrics, Gynecology, and Perinatology, Ministry of Health of Russia

Email: n_nazarova@oparina4.ru
MD, PhD, Senior Researcher

Vera Nikolaevna Prilepskaya

Research Center of Obstetrics, Gynecology, and Perinatology, Ministry of Health of Russia

Email: VPrilepskaya@mail.ru
MD, PhD, Professor, Deputy Director for Science

Guranda Merabovna Mzarelua

Research Center of Obstetrics, Gynecology, and Perinatology, Ministry of Health of Russia

Email: mzareluag@mail.ru
PhD student

Nonna Vladislavovna Bestaeva

Research Center of Obstetrics, Gynecology, and Perinatology, Ministry of Health of Russia

Email: nonnabestaeva@mail.ru
PhD student

Dmitriy Yur’evich Trofimov

Research Center of Obstetrics, Gynecology, and Perinatology, Ministry of Health of Russia

Email: d_troflmov@oparina4.ru
MD, PhD, Molecular-genetic Laboratory Chief

Gennadiy Tikhonovich Sukhikh

Research Center of Obstetrics, Gynecology, and Perinatology, Ministry of Health of Russia

Email: g_sukhikh@oparina4.ru
Academician of RAMS, MD, PhD, Professor, Director

References

  1. Parkin D.M., Bray F., Ferlay J., Pisani P. Global cancer statistics, 2002. CA Cancer J. Clin. 2005; 55(2): 74-108.
  2. Available at: http://www.cancer.org/cancer/cervicalcancer/detailedguide/ cervical-cancer-key-statistics
  3. Ostor A.G. Natural history of cervical intraepithelial neoplasia: a critical review. Int. J. Gynecol. Pathol. 1993; 12(2): 186-92.
  4. Nishio S., Fujii T., Nishio H., Kameyama K., Saito M., Iwata T. et al. P16(INK4a) immunohistochemistry is a promising biomarker to predict the outcome of low grade cervical intraepithelial neoplasia: comparison study with HPV genotypin. J. Gynecol. Oncol. 2013; 24(3): 215-21.
  5. Solomon D., Nayar R., eds. The Bethesda system for reporting cervical cytology: definitions, criteria and explanatory notes. 2nd ed. New York, NY: Springer; 2004: 169-75.
  6. Сухих Г.Т., Прилепская В.Н., ред. Профилактика рака шейки матки. Руководство для врачей. 3-е изд. М.: МЕДпресс-информ; 2012.192с. [Sukhikh G.T., Prilepskaya V.N., eds. Prevention of cervical cancer. Guide for physicians. 3rd ed. Moscow: MEDpress-Inform; 2012.192p. (in Russian)]
  7. Роговская С.И. Папилломавирусная инфекция у женщин и патология шейки матки. В помощь практикующему врачу. 2-е изд. М.: ГЭОТАР-Медиа; 2008.192с. [Rogovskaya S.I. HPV infection in women, and pathology of the cervix. To help the practitioner. 2nd ed. Moscow: GEOTAR Media; 2008.192p. (in Russian)]
  8. Boyle P., Autier P., Bartelink H., Baselga J., Boffetta P., Burn J. et al. European Code Against Cancer and scientific justification: third version (2003). Ann. Oncol. 2003; 14(7): 973-1005.
  9. Munakata S., Watanabe O., Ohashi K., Morino H. Expression of Fas ligand and bcl-2 in cervical carcinoma and their prognostic significance. Am. J. Clin. Pathol. 2005; 123(6): 879-85.
  10. zur Hausen H. Papillomaviruses causing cancer: evasion from host-cell control in early events in carcinogenesis. J. Natl. Cancer Inst. 2000; 92(9): 690-8.

Supplementary files

Supplementary Files
Action
1. JATS XML

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies